EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Effectiveness and Safety of Radium‐223 for Bone‐Metastatic Castration‐Resistant Prostate Cancer: The KYUCOG ‐1901 Study

Masaki Shiota iD, Shuichi Tatarano, Tomomi Kamba, Toshiyuki Kamoto, Tsukasa Igawa, Naoya Masumori, Hirotsugu Uemura iD, Kensuke Mitsunari, Takayuki Sumiyoshi, Hiroji Uemura, Katsuyoshi Higashijima, Shoji Tokunaga und 1 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70293 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Science, 2026. Verfasst von Masaki Shiota und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Radium, Bone Neoplasms, Antineoplastic Agents. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radium‐223 dichloride (Ra‐223) improves survival in bone‐metastatic castration‐resistant prostate cancer (mCRPC). However, prospective real‐world data are limited, particularly regarding treatment outcomes, predictors of completing six cycles, and integration with subsequent therapies. The KYUCOG‐1901 study was a prospective multicenter observational study at 19 Japanese institutions. Patients with mCRPC and ≥ 2 bone metastases received up to six cycles of Ra‐223. Effectiveness was assessed by PSA, alkaline phosphatase (ALP), time to visceral metastasis, time to cytotoxic chemotherapy, radiographic progression‐free survival (PFS), and overall survival (OS). Safety was evaluated using CTCAE v5.0. Of 101 enrolled, 93 patients were analyzed. Median follow‐up was 25.2 months. Early discontinuation was associated with high baseline PSA, ALP, LDH, and symptomatic disease. Subsequent therapies, including taxanes and androgen receptor signaling inhibitors (ARSIs), were administered in most patients. Maximum PSA and ALP declines of ≥ 30% were achieved in 16 (17.2%) and 39 (41.9%) patients, respectively. Median time to visceral metastasis, time to cytotoxic chemotherapy, radiographic PFS (rPFS), and OS were 32.9, 13.7, 8.8, and 23.0 months, respectively. Grade ≥ 3 adverse events occurred in 36.5%. No treatment‐related deaths were reported. Ra‐223 was effective and well tolerated in Japanese mCRPC patients. Early initiation in less symptomatic patients with lower disease burden may maximize benefit, and integration with subsequent therapies appears feasible. Trial Registration: University Hospital Medical Information Network Clinical Trials Registry UMIN000040358

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantRadiumBone NeoplasmsAntineoplastic AgentsHumansMaleAgedMiddle AgedProspective StudiesAged, 80 and overProstate-Specific AntigenTreatment OutcomeProgression-Free SurvivalRadioisotopesAlkaline Phosphatase

Stichwörter der Autor:innen

effectivenessprostate cancerradium‐223safety

Substanzen

Radiumradium Ra 223 dichlorideProstate-Specific AntigenRadium-223RadioisotopesAlkaline PhosphataseAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
  • Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Urology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
  • Department of Urology, School of Medicine, Kurume University, Kurume, Japan.
  • Department of Urology, School of Medicine, Sapporo Medical University, Sapporo, Japan.

ORCID-Profile: Masaki Shiota, Hirotsugu Uemura, Masatoshi Eto

Zitieren

APA

Shiota, M., Tatarano, S., Kamba, T., Kamoto, T., Igawa, T., Masumori, N., Uemura, H., Mitsunari, K., Sumiyoshi, T., Uemura, H., Higashijima, K., Tokunaga, S., & Eto, M. (2026). Effectiveness and Safety of Radium‐223 for Bone‐Metastatic Castration‐Resistant Prostate Cancer: The KYUCOG ‐1901 Study. Cancer Science. https://doi.org/10.1111/cas.70293

Vancouver

Shiota M, Tatarano S, Kamba T, Kamoto T, Igawa T, Masumori N, et al. Effectiveness and Safety of Radium‐223 for Bone‐Metastatic Castration‐Resistant Prostate Cancer: The KYUCOG ‐1901 Study. Cancer Science. 2026. doi:10.1111/cas.70293

BibTeX
@article{Shiota2026,
  author = {Shiota, Masaki and Tatarano, Shuichi and Kamba, Tomomi and Kamoto, Toshiyuki and Igawa, Tsukasa and Masumori, Naoya and Uemura, Hirotsugu and Mitsunari, Kensuke and Sumiyoshi, Takayuki and Uemura, Hiroji and Higashijima, Katsuyoshi and Tokunaga, Shoji and Eto, Masatoshi},
  title = {Effectiveness and Safety of Radium‐223 for Bone‐Metastatic Castration‐Resistant Prostate Cancer: The KYUCOG ‐1901 Study},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70293}
}
Kostenlos starten →